Report Details:
15 Companies Covered
90 Pages
Market Highlights
Global Fabry Disease Market Size was valued at USD 2,436.74 Million in 2024 & the market is projected to grow from USD 2,627.3 Million in 2025 to USD 5,578.42 Million by 2035, registering a CAGR of 7.82% during the forecast period 2025–2035. North America led the market with over 50.00% share, generating around USD 1218.4 Million in revenue.
Market growth is primarily driven by the rising prevalence of Fabry disease, advancements in enzyme replacement therapies (ERT), and the emergence of gene-based treatments. Increasing awareness, government support through orphan drug incentives, and growing R&D investments by 199 organizations worldwide are strengthening market expansion.
Recent regulatory milestones such as the FDA approval of Elfabrio for adult patients and the Fast Track Designation of isaralgagene civaparvovec underscore the rapid progress being made in developing novel treatment options.
MRFR recognizes the following companies as the key players in the Global Fabry Disease Market: Amgen Inc., Amicus Therapeutics Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis AG, Pfizer Inc., Protalix, Takeda Pharmaceutical Company Limited, AVROBIO, Idorsia Pharmaceuticals Ltd., Sanofi, Shire, Teva Pharmaceutical Industries Ltd., iBio, and Neuraltus Pharmaceuticals.
Segment Insights
The Global Fabry Disease Market has been segmented based on Type, Diagnosis & Treatment, End Users, and Region.
Based on Type, the market is divided into Type 1 (Classic) and Type 2 (Later-Onset) Fabry disease. The Type 2 segment dominates, as studies suggest its prevalence is 3–10 times higher than that of Type 1 in certain male populations (Chien et al., 2012).
By Diagnosis & Treatment, Diagnosis includes blood tests, urine tests, thyroid tests, lung function tests, imaging (EKG, echocardiogram, brain MRI, CT scan), hearing and eye examinations, and others. The treatment segment—comprising enzyme replacement therapy (ERT), gene therapy, pharmaceutical formulations containing agalsidase alfa, analgesics, anticonvulsants, and NSAIDs—held the largest share in 2024. ERT remains the leading therapy type, with drugs like Fabrazyme and Replagal addressing the root cause of Fabry disease. In August 2021, Amicus Therapeutics received European Commission approval for Galafold (migalastat) in adolescents aged 12–16 years, expanding treatment access globally.
Based on End Users, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, and Others. Hospitals & Clinics dominate the segment, supported by the increasing adoption of advanced diagnostics, government-backed infrastructure development, and the availability of skilled healthcare professionals.
Regional Analysis
By Region, the Global Fabry Disease Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
North America leads in the Fabry Disease Market size, accounting for over 50.00% of the global revenue in 2024. The region’s dominance is attributed to strong healthcare infrastructure, favorable reimbursement policies, and the presence of major pharmaceutical players.
Europe held the second-largest share, driven by the adoption of advanced chaperone and enzyme therapies, with the UK and Germany being key contributors.
Asia-Pacific (APAC) is anticipated to be the fastest-growing regional market, supported by rising healthcare expenditure, expanding diagnostic capabilities, and government support for rare disease management.
The Rest of the World, including Latin America and the Middle East, is witnessing steady growth, driven by improved access to treatments and awareness campaigns.
Key Findings of the Study
- North America leads the market with over 50.00% share in 2024.
- Europe reached USD 800 million in 2024, representing a 32.83% market share.
- Fabry Disease Market reached USD 2.44 billion in 2024, projected to reach USD 5.57 billion by 2035 at 7.82% CAGR.
